Arbutus Biopharma Corp
Research Arbutus Biopharma Corp (ABUS) on Bullrun: market cap USD 1.03B, P/E 6.6. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerABUS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.03B
- P/E6.6
- Financial periodQ1 2026
- RevenueUSD 179.13M
- Net incomeUSD 160.72M
- Free cash flow-USD 34.36M
Valuation Snapshot
latest market cap is USD 1.03B; P/E is 6.6.
Peer valuation comparison
Latest P/E is 6.64x versus a Healthcare sector median of 24.46x (72.9% below).
Latest P/E is 6.64x versus a United States median of 24.87x (73.3% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 14.08M | -USD 33.50M | -USD 39.64M | n/a | -0.17 | USD 18.01M | USD 0 | USD 76.58M |
| FY2024 | USD 6.17M | -USD 69.92M | -USD 65.03M | n/a | -0.38 | USD 36.33M | USD 0 | USD 97.37M |
| FY2023 | USD 18.14M | -USD 72.85M | -USD 86.94M | n/a | -0.44 | USD 26.29M | USD 0 | USD 106.02M |
| FY2022 | USD 39.02M | -USD 69.46M | -USD 35.87M | n/a | -0.46 | USD 30.78M | USD 0 | USD 136.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.03B | 6.6 | n/a | n/a |
| 2025 | 2025-12-31 | USD 926.08M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 621.18M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 419.24M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 364.57M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 564.00M | n/a | n/a | n/a |
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Arbutus Biopharma Corp's market cap?
Arbutus Biopharma Corp's market capitalization is USD 1.03B.
What is Arbutus Biopharma Corp's P/E ratio?
Arbutus Biopharma Corp's price-to-earnings (P/E) ratio is 6.6.
What does Arbutus Biopharma Corp do?
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1.